{"id":2531,"date":"2017-09-28T00:00:00","date_gmt":"2017-09-27T22:00:00","guid":{"rendered":"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/"},"modified":"2019-01-13T16:38:39","modified_gmt":"2019-01-13T15:38:39","slug":"28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12","status":"publish","type":"post","link":"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/","title":{"rendered":"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12"},"content":{"rendered":"<p><strong>Initial data supports penetration of NOX-A12 into tumor tissue and previously established safety profile of NOX-A12 monotherapy in colorectal and pancreatic cancer patients<\/strong><\/p>\n<p><strong>Berlin, Germany, September 28, 2017<\/strong> &#8211; NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), provided today an update on the ongoing Phase 1\/2 combination trial with NOXXON\u2019s lead cancer compound, NOX-A12 and Merck &amp; Co.\/MSD\u2019s Keytruda\u00ae (pembrolizumab) in pancreatic and colorectal cancer patients.<\/p>\n<p>The trial has enrolled 10 patients and therefore has successfully reached the halfway mark of the overall enrollment. The trial remains on schedule to deliver top-line biopsy analysis following NOX A12 monotherapy and top-line response rates for all 20 patients to NOX-A12 in combination with Keytruda\u00ae in the second and fourth quarters of 2018 respectively.<\/p>\n<p>Based on initial review of the two-week NOX-A12 monotherapy portion of the open-label study, NOX A12\u2019s safety and tolerability continue to be in line with previously reported and published data in that patients exhibit no major drug-related adverse effects. In addition, the currently available data from the first four enrolled patients suggest that NOX-A12 is able to penetrate into tumor tissue where it binds and neutralizes its target in both colorectal and pancreatic cancer patients. This analysis is based on levels of CXCL12 (C-X-C Chemokine Ligand 12), NOX-A12\u2019s target, and other biomarkers measured in tumor biopsies.<\/p>\n<p>\u201cWe are encouraged by the positive feedback we are receiving from clinicians and want to recognize their ongoing support and commitment to the study,\u201d said Aram Mangasarian, CEO of NOXXON. \u201cWe remain focused on meeting the trial timelines, which should enable us to deliver top-line data for both parts of the study in 2018.\u201d<\/p>\n<p>The primary purpose of part 1 of the trial is to confirm that treatment with NOX-A12 can modulate the tumor microenvironment including the type, number and\/or distribution of immune cells, such as cytotoxic T cells as well as chemokine and cytokine signatures in the tumor tissue. All patients completing part 1 move to part 2, in which they receive NOX-A12 in combination with Keytruda\u00ae. Part 2 is designed to explore the safety, tolerability and efficacy of NOX-A12 in combination with Keytruda\u00ae.<\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-2531\" data-postid=\"2531\" class=\"themify_builder_content themify_builder_content-2531 themify_builder tf_clear\">\n    <\/div>\n<!--\/themify_builder_content-->","protected":false},"excerpt":{"rendered":"<p>NOXXON Supervisory Board elects experienced US &amp; EU Biotech Veteran Don deBethizy Chairman<\/p>\n","protected":false},"author":1,"featured_media":2607,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12 - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12 - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"og:description\" content=\"NOXXON Supervisory Board elects experienced US &amp; EU Biotech Veteran Don deBethizy Chairman\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-27T22:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-01-13T15:38:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"norman.krey\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"norman.krey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/\"},\"author\":{\"name\":\"norman.krey\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\"},\"headline\":\"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12\",\"datePublished\":\"2017-09-27T22:00:00+00:00\",\"dateModified\":\"2019-01-13T15:38:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/\"},\"wordCount\":372,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"articleSection\":[\"Portfolio News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/\",\"url\":\"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/\",\"name\":\"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12 - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/#website\"},\"datePublished\":\"2017-09-27T22:00:00+00:00\",\"dateModified\":\"2019-01-13T15:38:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/dewb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dewb.de\/en\/#website\",\"url\":\"https:\/\/dewb.de\/en\/\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"description\":\"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website\",\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dewb.de\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dewb.de\/en\/#organization\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"url\":\"https:\/\/dewb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"contentUrl\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"width\":300,\"height\":82,\"caption\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\"},\"image\":{\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\",\"name\":\"norman.krey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"caption\":\"norman.krey\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12 - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/","og_locale":"en_US","og_type":"article","og_title":"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12 - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","og_description":"NOXXON Supervisory Board elects experienced US &amp; EU Biotech Veteran Don deBethizy Chairman","og_url":"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/","og_site_name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","article_published_time":"2017-09-27T22:00:00+00:00","article_modified_time":"2019-01-13T15:38:39+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png","type":"image\/png"}],"author":"norman.krey","twitter_card":"summary_large_image","twitter_misc":{"Written by":"norman.krey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/#article","isPartOf":{"@id":"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/"},"author":{"name":"norman.krey","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b"},"headline":"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12","datePublished":"2017-09-27T22:00:00+00:00","dateModified":"2019-01-13T15:38:39+00:00","mainEntityOfPage":{"@id":"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/"},"wordCount":372,"commentCount":0,"publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"articleSection":["Portfolio News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/","url":"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/","name":"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12 - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","isPartOf":{"@id":"https:\/\/dewb.de\/en\/#website"},"datePublished":"2017-09-27T22:00:00+00:00","dateModified":"2019-01-13T15:38:39+00:00","breadcrumb":{"@id":"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dewb.de\/en\/28-09-17-noxxon-provides-update-on-ongoing-phase-1-2-clinical-trial-with-lead-program-nox-a12\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/dewb.de\/en\/"},{"@type":"ListItem","position":2,"name":"NOXXON provides Update on ongoing Phase 1\/2 clinical Trial with Lead Program NOX-A12"}]},{"@type":"WebSite","@id":"https:\/\/dewb.de\/en\/#website","url":"https:\/\/dewb.de\/en\/","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","description":"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website","publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dewb.de\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dewb.de\/en\/#organization","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","url":"https:\/\/dewb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","contentUrl":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","width":300,"height":82,"caption":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG"},"image":{"@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b","name":"norman.krey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","caption":"norman.krey"}}]}},"builder_content":"","_links":{"self":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2531"}],"collection":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/comments?post=2531"}],"version-history":[{"count":3,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2531\/revisions"}],"predecessor-version":[{"id":2646,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2531\/revisions\/2646"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media\/2607"}],"wp:attachment":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media?parent=2531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/categories?post=2531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/tags?post=2531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}